Opus Genetics clears early BEST1 bar as 75% hit FDA-aligned endpoint

The readout clears the early clinical bar rather than merely confirming safety. The market already knew the September 2026 data event was coming, and prior updates had established a clean early safety profile; the new information is that low-dose treatment produced a coherent efficacy signal across retinal structure and function. The filing reports no serious adverse events, dose-limiting toxicities or intraocular inflammation in all five participants. 〔0〕

The strongest result was on the endpoint now being considered for pivotal development. Three of four evaluable participants, or 75%, achieved at least a 3 dB improvement across five or more loci in the treated retinal transition zone, the area surrounding damaged retina that may still be functional. That is materially better than a purely exploratory imaging result because the FDA has discussed this type of microperimetry measure, alongside a randomized trial and patient-reported outcome, as a potential Phase 3 endpoint.

The structural findings reinforce the functional signal, but the evidence remains very small and uncontrolled. Four of five participants showed structural improvement; vitelliform material declined in two of three BVMD patients and intraretinal fluid declined in both ARB patients. 〔1〕 The caveat is important: this was an open-label, five-person cohort, microperimetry was not prespecified in the highlighted participant case studies, and the most advanced BVMD patient experienced a 0.2 logMAR decline in vision. The response appears strongest in earlier-stage disease, which helps enrollment strategy but narrows how broadly the result can be generalized.

The filing advances the program beyond a data release into a credible pivotal path. Cohort 2 is already over-enrolled at eight participants, with dosing expected to finish in the fourth quarter of 2026 and topline data targeted for the second quarter of 2027. 〔2〕 The August 2026 FDA meeting also produced alignment on potential pivotal endpoints and Phase 3 manufacturing requirements, while pivotal dosing is targeted for 2027. 〔3〕 Net: this is a meaningful positive surprise versus the minimum expected from a tiny first-in-human cohort, though the higher-dose readout must show the signal is reproducible before the pivotal thesis is truly de-risked.